Brand Name(s): Adapin, Sinequan
CAS nº: 1668-19-5
(dox‘ e pin)
About Doxepin
This new site is dedicated exclusively to doxepin.
It provides you with the most extensive product information and up-to-date resources regarding this medication, including related news articles, medical studies, an image library and all the necessary information on dosage and side effects.
Whether you are an average consumer or a pharma industry professional, you can now find out everything you need to know about doxepin on this reference site, as well as take part in our open discussion forum by sharing your own knowledge and experience with people who are using this medication.
This unique site will also provide you with inside industry news on which companies or organizations are playing an important part in its research, development, production and promotion. It is your one-stop site for a total doxepin experience!
Why is this medication prescribed?
Doxepin is in a class of drugs called tricyclic antidepressants. It works by affecting chemicals in the brain that may become unbalanced and cause depression.
Doxepin is used to relieve symptoms of depression and anxiety such as feelings of sadness, worthlessness, or guilt, as well as loss of interest in daily activities, changes in appetite, tiredness, sleeping too much, insomnia, and thoughts of death or suicide.
Latest News
Clinical Data on Somaxon Pharmaceuticals' Product Candidate for the Treatment of Insomnia Presented at American Psychiatric Association Annual Meeting
Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company focused on the...
[more]Somaxon Pharmaceuticals Submits New Drug Application for SILENOR(TM) for the Treatment of Insomnia
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing and...
[more]Low Dose Doxepin is Safe and Effective in Chronic Primary Insomnia Patients
Chronic insomnia is prevalent in almost 10% of the adult population, and primary insomnia has been...
[more]Somaxon Pharmaceuticals Provides Update On SILENOR(TM) Development Program For The Treatment Of Insomnia
Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) today is providing information on its development...
[more]Going off depression medications risks relapse
Patients with diabetes (who need insulin chronically) and patients with hypertension (who take...
[more]